By: Adriana Rossi, Sagar Lonial
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.



